Mesenchymal stem cell therapy and cognition in MS : Preliminary findings from a phase II clinical trial
Copyright © 2022. Published by Elsevier B.V..
BACKGROUND: Mesenchymal stem cell (MSC) therapies are being evaluated in multiple sclerosis (MS) for possible neural repair. To date, the potential benefits on cognition have received little attention. The objective of the current study was to comprehensively evaluate cognition before and after MSC therapy in those with MS as part of a double-blind, phase II clinical trial.
METHODS: Twenty-eight individuals with a confirmed diagnosis of MS were randomly assigned into two study arms. Cognition was evaluated using an expanded Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery. The battery was administered at Week 0, Week 24, and Week 48 and results were analysed at the group and individual level.
RESULTS: No detectable effect of MSC-mediated neural repair was noted in the short-term with respect to cognition, although some cognitive stability or improvement was observed. Decline was noted in some cognitive areas immediately following the procedure at Week 24; though these were temporary with performance returning to baseline levels at Week 48.
CONCLUSIONS: While MSC therapy does not lead to improvement in cognition, at least in the short-term, neither does the procedure have lasting deleterious effects. The current findings lend support to the safety and feasibility of MSC therapy as a potentially viable treatment option for individuals with MS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Multiple sclerosis and related disorders - 61(2022) vom: 21. Mai, Seite 103779 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berard, Jason A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase II |
|---|
| Anmerkungen: |
Date Completed 08.06.2022 Date Revised 08.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.msard.2022.103779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338977627 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338977627 | ||
| 003 | DE-627 | ||
| 005 | 20231226001900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2022.103779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM338977627 | ||
| 035 | |a (NLM)35367874 | ||
| 035 | |a (PII)S2211-0348(22)00294-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berard, Jason A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mesenchymal stem cell therapy and cognition in MS |b Preliminary findings from a phase II clinical trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2022 | ||
| 500 | |a Date Revised 08.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Mesenchymal stem cell (MSC) therapies are being evaluated in multiple sclerosis (MS) for possible neural repair. To date, the potential benefits on cognition have received little attention. The objective of the current study was to comprehensively evaluate cognition before and after MSC therapy in those with MS as part of a double-blind, phase II clinical trial | ||
| 520 | |a METHODS: Twenty-eight individuals with a confirmed diagnosis of MS were randomly assigned into two study arms. Cognition was evaluated using an expanded Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery. The battery was administered at Week 0, Week 24, and Week 48 and results were analysed at the group and individual level | ||
| 520 | |a RESULTS: No detectable effect of MSC-mediated neural repair was noted in the short-term with respect to cognition, although some cognitive stability or improvement was observed. Decline was noted in some cognitive areas immediately following the procedure at Week 24; though these were temporary with performance returning to baseline levels at Week 48 | ||
| 520 | |a CONCLUSIONS: While MSC therapy does not lead to improvement in cognition, at least in the short-term, neither does the procedure have lasting deleterious effects. The current findings lend support to the safety and feasibility of MSC therapy as a potentially viable treatment option for individuals with MS | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Cognition | |
| 650 | 4 | |a Mesenchymal stem cells | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a Stem cell therapy | |
| 700 | 1 | |a Freedman, Mark S |e verfasserin |4 aut | |
| 700 | 1 | |a Marrie, Ruth Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Marriott, James J |e verfasserin |4 aut | |
| 700 | 1 | |a Atkins, Harold L |e verfasserin |4 aut | |
| 700 | 1 | |a Szwajcer, David |e verfasserin |4 aut | |
| 700 | 1 | |a Courtman, David W |e verfasserin |4 aut | |
| 700 | 1 | |a Thebault, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Lisa A S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 61(2022) vom: 21. Mai, Seite 103779 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g day:21 |g month:05 |g pages:103779 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2022.103779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |b 21 |c 05 |h 103779 | ||